Table 5.

Secondary outcomes

	Control (n = 90)	Remdesivir (n = 82)	Sotrovimab (n = 88)	P
COVID-19-related 29 day hospitalization, n (%)	11 (12.2)	7 (8.5)	7 (8)	0.58
COVID-19-related 29 day ED visit, n (%)	10 (11.1)	2 (2.4)	1 (1.2)	0.004
remdesivir versus control	unadjusted OR = 0.2 (95% CI = 0.04–0.94)			0.04
sotrovimab versus control	unadjusted OR = 0.09 (95% CI = 0.01–0.73)			0.02
COVID-19-related 14 day hospitalization, n (%)	8 (8.9)	4 (5)	3 (3.4)	0.27
COVID-19-related 14 day ED visit, n (%)	6 (6.7)	1 (1.2)	1 (1.2)	0.05
29 day all-cause mortality, n (%)	1 (1.1)	0 (0)	0 (0)	0.39
Adverse drug event, n (%)	-	1 (1.2)	1 (1.2)	0.96